

February 12, 2025

To
The Secretary, Listing Department
BSE Limited (SME),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Sub: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find attached herewith the Integrated Filing (Financial) for the quarter/nine months ended December 31, 2024.

The above information is also available on the website of the Company
<https://www.prevestdenpro.com/q3-24-25/>

Please acknowledge and take the same on your records.

Thanking You,

Yours faithfully,

For Prevest Denpro Limited

Aman Sadhotra
(Company Secretary and Compliance Officer)

Encl: as above

Unaudited Standalone Financials Results for the Quarter and Nine Months ended on 31st December, 2024

in Lakh

PARTICULARS	Quarter Ended			Nine Month Ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
Revenue from operations	1,492.62	1,625.67	1,362.32	4,452.52	4,019.50	5,643.98
Other Income	109.77	106.56	67.94	302.76	202.18	286.16
Total Income	1,602.39	1,732.23	1,430.27	4,755.28	4,221.68	5,930.14
2 Expenses						
(a) Cost of Material Consumed	327.91	381.67	306.21	1,000.06	1,010.05	1,417.33
Purchase of Stock-in- Trade	-	-	-	-	-	-
(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.24	(10.32)	(3.11)	(19.31)	(17.41)	(17.99)
(c) Finance Cost	-	-	-	-	-	-
(d) Employee benefit expenses	257.77	260.34	239.56	767.05	709.88	953.99
(e) Depreciation and amortization expenses	48.22	47.12	42.06	143.04	81.50	127.63
(f) Other Expenses	392.72	412.59	372.19	1,160.64	922.26	1,307.72
Total Expenses	1,026.86	1,091.41	956.91	3,051.47	2,706.27	3,788.69
3 Profit Before Tax (1-2)	575.53	640.82	473.36	1,703.81	1,515.40	2,141.46
4 Tax Expenses						
Current Tax	135.76	150.95	105.27	399.48	354.50	497.52
Earliyer Year Tax	-	0.32	-	0.32	-	-
Deffered Tax	-6.60	5.71	4.56	8.65	14.88	31.57
Total Tax Expenses	129.16	156.97	109.83	408.45	369.38	529.09
5 Net Profit for the Peiod/Year (3-4)	446.37	483.85	363.53	1,295.36	1,146.02	1,612.37
6 Earnings per Share (EPS) , in Rs (not annualised) (Equity Share of face value of Rs 10/- each)						
(a) Basic	3.72	4.03	3.03	10.79	9.55	13.44
(b) Diluted	3.72	4.03	3.03	10.79	9.55	13.44
7 Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00	120.00	120.00
8 Reserve (excluding Revaluation Reserves)						7,660.12

Notes:-

- The above financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Saturday, 01st February 2025. The above results have been subject to limited review by the Statutory Auditor of the Company.
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India.
- The figures for the previous period have been restated / regrouped / reclassified, wherever necessary, in order to make them comparable.

 Atul Modi
 (Managing Director)

DIN-00788272





Independent Auditor's Report on Review of Unaudited Standalone Financial Results

To
The Board of Directors
Prevest Denpro Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Prevest Denpro Limited (the Company) for the quarter ended December 31, 2024 and the year-to-date results for the period April 01, 2024 to December 31, 2024, ("the Statement"). This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates.,
Chartered Accountants
FRN: 106456W


Sourabh Bagaria
Partner
Membership No 183850
UDIN: - 25183850BMKYZL6930



Date: February 01, 2025
Place: Mumbai

Unaudited Consolidated Financials Results for the Quarter and Nine Months ended on 31st December 2024

Rs. In Lakhs

PARTICULARS	Quarter Ended			Nine Month Ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from Operations	1,494.68	1,627.09	1,362.45	4,457.33	4,019.38	5,642.89
(b) Other Income	108.88	103.75	67.94	299.07	202.18	286.17
Total Income	1,603.57	1,730.85	1,430.39	4,756.40	4,221.56	5,929.05
2 Expenses						
(a) Cost of Material Consumed	327.91	381.67	306.21	1,000.06	1,010.05	1,375.58
(b) Purchase of Stock-in- Trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	(0.01)	(11.02)	(3.06)	(20.31)	(17.60)	(19.99)
(d) Finance Cost	-	-	-	-	-	-
(d) Employee benefit expenses	288.51	289.17	252.38	845.97	730.70	987.81
(e) Depreciation and amortization expenses	48.26	47.14	42.06	143.09	81.50	127.63
(f) Other Expenses	357.12	386.11	359.35	1,077.73	911.16	1,314.80
Total Expenses	1,021.79	1,093.06	956.94	3,046.53	2,715.81	3,785.83
3 Profit before Tax (1-2)	581.78	637.79	473.45	1,709.87	1,505.75	2,143.22
4 Tax Expenses						
Current Tax	135.76	150.23	105.27	399.48	354.50	497.96
Earliyer Year Tax	-	0.32	-	0.32	-	-
Deffered Tax	-6.60	5.71	4.55	8.65	14.88	31.57
Total Tax Expenses	129.16	156.26	109.82	408.45	369.38	529.53
5 Net profit for the period / year (3-4)	452.61	481.53	363.63	1,301.41	1,136.37	1,613.69
6 Earnings per Share (EPS) , in Rs (not annualised)						
(a) Equity Share of face value of Rs 10/- each						
(a) Basic	3.77	4.01	3.03	10.84	9.47	13.45
(b) Diluted	3.77	4.01	3.03	10.84	9.47	13.45
7 Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00	120.00	120.00
8 Reserves (Excluding revaluation reserve)						7,660.12

Notes:-

- The above consolidated financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Saturday, 01st February 2025. The above results have been subject to limited review by the Statutory Auditor of the Company.
- This consolidated financial result includes, results of Denvisio Biomed Limited (Wholly Owned Subsidiary of Prevest Denpro Limited)
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above consolidated Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India.
- The figures for the previous period have been restated / regrouped / reclassified, wherever necessary, in order to make them comparable.


Atul Modi
 (Managing Director)
 DIN-00788272




Independent Auditor's Report on Review of Unaudited Consolidated Financial Results

To
The Board of Directors
Prevest Denpro Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Prevest Denpro Limited ("the Parent") and its subsidiary (the parent and its subsidiary together referred to as "the group") for the quarter ended December 31, 2024 and year to date results for the period April 01, 2024 to December 31, 2024 ("the Statement").

This statement is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

Holding/parent Company: - Prevest Denpro Limited
Subsidiary Company: - Denvio Biomed Limited

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates.,
Chartered Accountants
FRN: 106456W

Sourabh
Sourabh Bagaria
Partner
Membership No 183850
UDIN: - 25183850BMKYZM8020



Date: February 01, 2025
Place: Mumbai

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Statement of Deviation / Variation in utilization of funds raised in IPO

Name of the listed Entity	Prevest Denpro Limited
Mode of Fund raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds	September 22, 2021 (Date of Allotment)
Amount Raised	Fresh Issue - INR 2661.12 lakhs
Report filed for the Quarter ended	December 31, 2024
Monitoring Agency	Applicable / Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	Yes / No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If yes, Date of shareholders' Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the Auditors if any	Nil

Objects for which funds have been raised and where there has been a deviation, in the following table				1.Purchase of machineries, equipment's and utilities for manufacturing of proposed additional line of products, R&D unit and existing manufacturing operations 2.General Corporate Purpose 3. To meet issue expenses		
Original Object	Modified Object, if any	Original Allocation	Modified Allocation,if any	Funds Utilised	Amount of Deviation / Variation for the quarter according to applicable object	Remarks,if any
Not applicable as no deviation from the objects						

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed;
- or
- (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc.

Thanking you,

For **Prevest Denpro Limited**

Namrata Modi
Whole time Director and CFO
DIN- 00788266

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTION (APPLICABLE ONLY FOR HALF – YEARLY FILINGS I.E. 2ND AND 4TH QUARTER)

Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUIFICATION (FOR AUDIT REPORT WITH MODIFIED OPINION SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (APPLICABLE ONLY FOR ANNUAL FILING I.E., 4TH QUARTER)

Not Applicable

Thanking You,

Yours faithfully,

For Prevest Denpro Limited

Aman Sadhotra
(Company Secretary and Compliance Officer)